William Segal, MD
Ophthalmology · Duluth, GANPI 1275698516
Payments from drug & device makers
Across 247 payments — averaging $37.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- Oyster Point Pharma, Inc.$465
- Mallinckrodt Hospital Products Inc.$428
- Bausch & Lomb Americas Inc.$240
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,10599%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 55 | $2,778 |
| Sun Pharmaceutical Industries Inc. | 44 | $1,401 |
| AbbVie(2 entities) | 26 | $1,359 |
| Oyster Point Pharma, Inc. | 17 | $465 |
| Mallinckrodt Hospital Products Inc. | 16 | $428 |
| Bausch & Lomb Americas Inc. | 12 | $240 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $233 |
| Kala Pharmaceuticals, Inc. | 11 | $225 |
| Dompe US, Inc. | 8 | $209 |
| Biotissue Holdings Inc. | 5 | $203 |
| Lensar, Inc. | 1 | $163 |
| Rxsight Inc | 2 | $158 |
| Glaukos Corporation | 1 | $146 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $108 |
| Novartis | 6 | $102 |
| Lombart Brothers, Inc. | 1 | $97 |
| Iridex Corporation | 2 | $97 |
| Amgen | 3 | $93 |
| Harrow Eye, LLC | 4 | $90 |
| Sight Sciences, Inc. | 3 | $85 |
| Akorn, Inc. | 1 | $85 |
| Merz Pharmaceuticals, LLC | 3 | $84 |
| Tarsus Pharmaceuticals, Inc. | 4 | $84 |
| Thea Pharma Inc. | 3 | $58 |
| Shire North American Group Inc | 3 | $54 |
| Rayner Intraocular Lenses Limited | 2 | $41 |
| Eyevance Pharmaceuticals LLC | 2 | $38 |
| Astellas Pharma US Inc | 1 | $27 |
| Carl Zeiss Meditec USA, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$470
- Clareon$318
- ORA System VerifEye$278
- ARGOS$267
- BROMSITE$227
- LENSAR LASER SYSTEM$163
- Clareon PanOptix Pro$150
- Prokera$144
- AmnioGraft$144
- ReSTOR$142
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$131
- AMO PHACO NEEDLE$130
- TYRVAYA$120
- XELPROS$116
- Unity$102
How this compares
$9,181 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 48 | $61,345 |
| RestasisCyclosporine | 33 | $31,501 |
| TyrvayaVarenicline Tartrate | 24 | $20,398 |
| LumiganBimatoprost | 25 | $15,152 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $13,963 |
| Latanoprost | 498 | $6,795 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,626 |
| VyzultaLatanoprostene Bunod | 17 | $6,536 |
| Travoprost | 18 | $4,007 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $3,401 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $3,390 |
| Prednisolone Acetate | 80 | $2,660 |
| ValacyclovirValacyclovir Hcl | 20 | $2,005 |
| Azelastine Hcl | 98 | $1,959 |
| Timolol Maleate | 198 | $1,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $240 | $67,88165 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,359 | $53,27977 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $465 | $20,39824 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $108 | $1,21813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Duluth
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.